275 related articles for article (PubMed ID: 19615897)
1. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and kinase inhibitory activity of novel substituted indigoids.
Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
[TBL] [Abstract][Full Text] [Related]
4. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
Park A; Hwang J; Lee JY; Heo EJ; Na YJ; Kang S; Jeong KS; Kim KY; Shin SJ; Lee H
Bioorg Med Chem Lett; 2021 Sep; 47():128226. PubMed ID: 34182093
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors.
Shi J; Xu G; Zhu W; Ye H; Yang S; Luo Y; Han J; Yang J; Li R; Wei Y; Chen L
Bioorg Med Chem Lett; 2010 Jul; 20(14):4273-8. PubMed ID: 20621733
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
[TBL] [Abstract][Full Text] [Related]
16. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P
Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128
[TBL] [Abstract][Full Text] [Related]
20. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.
Tell V; Holzer M; Herrmann L; Mahmoud KA; Schächtele C; Totzke F; Hilgeroth A
Bioorg Med Chem Lett; 2012 Nov; 22(22):6914-8. PubMed ID: 23039927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
